1. MYCN

    Comments Leave a Comment

    1-15 of 221 1 2 3 4 ... 13 14 15 »
    1. Mentioned In 221 Articles

    2. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.

      ...PRC2 in HR-NB cells. A significant concurrence existed between exons with verified variants and genes showing MYCN-dependent expression in HR-NB. From these biomarker candidates, we identified two novel prognostic gene-s...
      Read Full Article
      Mentions: MYCN
    3. Validation of post-induction Curie scores in high risk neuroblastoma. A Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1.

      ...re maintained independent statistical significance in Cox models, when adjusted for the covariates of age and MYCN (V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog) gene copy number. Conclusion:...
      Read Full Article
      Mentions: Staging SIOPEN COG
    4. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

      ...om diagnosis to first disease recurrence/progression was 18.7 months (range, 1.4-64.8 months) (176 patients). MYCN amplification and 11q loss of heterozygosity were prognostic of worse PFS and OS (P = .003 and P<.0001, r...
      Read Full Article
      Mentions: COG Refractory MYCN
    5. Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on (123)I-MIBG SPECT predict the outcome?

      ...analysis were ASP (p = 0.029; hazard ratio, HR, 1.032 for a one unit increase), MTV (p = 0.038; HR 1.012) and MYCN amplification status (p = 0.047; HR 4.67). The mean EFS in patients with high ASP (>32.0%) and low ASP we...
      Read Full Article
      Mentions: Imaging MYCN MIBG
    6. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

      ...patients with localized neuroblastoma age 18 months or older, especially in INRG high-risk patients harboring MYCN amplification, extended surgery of the primary tumor site improved local control rate and survival with a...
      Read Full Article
      Mentions: INRG Imaging MYCN
    7. 1-15 of 221 1 2 3 4 ... 13 14 15 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Quotes about MYCN

    1. Children with a MYCN-amplification event, which occurs in about 25 percent of cases, have the poorest prognosis.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    2. Once a tumor has disrupted let-7 genetically, it doesn't need to amplify MYCN because it doesn't need to sponge let-7.
      In Loss of a microRNA family, let-7, found key in neuroblastoma
    3. We showed that maintenance of high MYCN protein levels is a key issue for this MYCN driven cancer. Neuroblastoma cells often have over 100 copies of the MYCN gene - so they produce an enormous amount of MYCN protein.
      In A way to target the Achilles heel of neuroblastoma